Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Change in Accured Expenses: 2021-2025

Historic Change in Accured Expenses for Roivant Sciences (ROIV) over the last 5 years, with Mar 2025 value amounting to -$10.1 million.

  • Roivant Sciences' Change in Accured Expenses fell 40.69% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.9 million, marking a year-over-year decrease of 304.80%. This contributed to the annual value of -$10.1 million for FY2025, which is 125.08% down from last year.
  • According to the latest figures from FY2025, Roivant Sciences' Change in Accured Expenses is -$10.1 million, which was down 125.08% from $40.1 million recorded in FY2024.
  • Over the past 5 years, Roivant Sciences' Change in Accured Expenses peaked at $50.6 million during FY2022, and registered a low of -$10.1 million during FY2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was $39.0 million (2023), whereas its average is $23.0 million.
  • As far as peak fluctuations go, Roivant Sciences' Change in Accured Expenses soared by 448.46% in 2022, and later plummeted by 125.08% in 2025.
  • Yearly analysis of 5 years shows Roivant Sciences' Change in Accured Expenses stood at $9.2 million in 2021, then soared by 448.46% to $50.6 million in 2022, then declined by 23.00% to $39.0 million in 2023, then rose by 3.06% to $40.1 million in 2024, then crashed by 125.08% to -$10.1 million in 2025.